GS-1179
From EverybodyWiki Bios & Wiki
Comment: Neither of the sources cited is significant, independent coverage. One is a patent review (non-independent) and the other is a press release (non-independent and trivial coverage). We need significant coverage in at least 2 secondary sources to meet WP:GNG. WeirdNAnnoyed (talk) 23:19, 17 August 2026 (UTC)
GS-1179 (formerly ABI-1179) is an anti-herpetic drug candidate[1] being developed by a partnership between Assembly Biosciences and Gilead Sciences.[2]
References
- ↑ Gege, Christian; Kleymann, Gerald (October 2024). "Helicase-primase inhibitors for the treatment of herpes simplex virus infections - patent evaluation of WO2023/225162 from Gilead Sciences Inc". Expert Opinion on Therapeutic Patents. 34 (10): 863–872. doi:10.1080/13543776.2024.2403618. ISSN 1744-7674. PMID 39262042 Check
|pmid=value (help). - ↑ "Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase Primase Inhibitor Programs for Recurrent Genital Herpes". www.gilead.com. Retrieved 2026-08-17.
This article "GS-1179" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:GS-1179. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
